Leptin Signaling at the Crossroads of Obesity, Immunity, and Cancer: Mechanistic Insights and Therapeutic Implications Authors: Gitima Deka, Pil-Hoon Park Published: 2026 ABSTRACT Leptin, an adipokine predominantly secreted by adipose tissue, has exhibited a wide range of biological functions, including regulation of energy balance, appetite, and metabolism. Accumulating evidence has demonstrated that leptin also plays a role in obesity-associated tumor progression. Elevated circulating leptin levels in obese individuals, together with the close association between obesity and increased cancer risk, have led to growing interest in leptin as a potential mediator linking adiposity to tumor growth and immune dysregulation. Recent studies have shown that leptin can directly interact with immune cells within the tumor microenvironment and promote dysfunction or exhaustion in various immune cell populations, thereby impairing anti-tumor immunity. These findings suggest that tumor-promoting effects of leptin may be mediated, at least in part, through modulation of anti-tumor immune responses. Notably, metabolic reprogramming of both immune cells and cancer cells appears to be a critical mechanism underlying leptin-mediated tumor progression and immune dysfunction. Since obesity is characterized by altered adipokine production, chronic low-grade inflammation, and immune dysregulation, leptin may serve as a critical mediator linking excess adiposity to impaired immune surveillance and cancer progression. However, the biological effects of leptin are highly context-dependent. Although leptin predominantly supports tumor progression and immune suppression in many obesity-associated cancers, it may also exert immune-stimulatory or anti-tumor effects under specific conditions. This review summarizes current mechanistic insights into the role of leptin in tumor progression and immune regulation. We also highlight therapeutic strategies that integrate leptin-targeted approaches with immunotherapy. INTRODUCTION Adipose tissue was long regarded primarily as an energy-storing organ until leptin was isolated and identified as an adipocyte-derived hormone encoded by the ob gene (Zhang et al., 1994). The discovery of leptin reshaped the concept of adipose tissue from a passive lipid storage depot into a dynamic endocrine organ that regulates a wide range of physiological processes (Friedman, 2019, 2014). Leptin plays a central role in systemic energy homeostasis by modulating appetite, energy expenditure, neuroendocrine function, and metabolic adaptation (Friedman and Halaas, 1998). For example, reduced leptin signaling lowers thyroid and sympathetic tone, thereby decreasing total energy expenditure and reproductive function (Park and Ahima, 2015). Consistently, leptin-deficient ob/ob mice exhibit hyperphagia, severe obesity, and insulin resistance, whereas leptin administration reverses many of these abnormalities, highlighting the critical role of leptin signaling in systemic metabolic regulation (Friedman and Halaas, 1998). Beyond its classical metabolic functions, leptin is now recognized as a multifunctional adipokine that exerts diverse physiological effects, including regulating immune responses, inflammation, and neuroendocrine signaling. In obesity, circulating leptin levels are markedly elevated in proportion to increased adiposity, whereas leptin sensitivity is often impaired, resulting in a state commonly referred to as leptin resistance. Importantly, persistent hyperleptinemia under obese conditions is increasingly recognized as an endocrine and immunometabolic signal that contributes to the development and progression of obesity-associated pathologies, including cancer. Recent epidemiological and experimental evidence support a close association between excess adiposity and increased cancer risk. Obesity-associated inflammation and altered adipokine production may promote the development of a tumor-permissive microenvironment (Iyengar et al., 2016). Accumulating evidence indicates that leptin promotes tumor progression through multiple mechanisms, including stimulation of cancer cell proliferation, survival, metastasis, angiogenesis, and resistance to anti-cancer therapy (Lin and Hsiao, 2021). Accordingly, earlier studies on the tumor-promoting effects of leptin primarily focused on its direct actions on cancer cells, particularly its ability to activate oncogenic signaling pathways, such as JAK2/STAT3, PI3K/AKT, MAPK/ERK, NF-κB, and mTOR signalling, regulating key tumor-associated processes, including proliferation, apoptosis resistance, epithelial–mesenchymal transition, angiogenesis, and metabolic adaptation (Gu et al., 2019; Lin and Hsiao, 2021). These findings have contributed to identifying leptin-related signaling pathways as potential pharmacological targets for controlling tumor growth. More recently, increasing attention has been directed toward the role of leptin in shaping the immune responses, particularly within the tumor immune microenvironment. Obesity is characterized not only by metabolic dysfunction but also by chronic low-grade inflammation and immune dysregulation, both of which can create a tumor-permissive environment (Iyengar et al., 2016). Leptin receptors are expressed on various immune cell populations, including macrophages, dendritic cells (DC), natural killer (NK) cells, T cells, and B cells, enabling leptin to directly modulate immune cell activation, differentiation, and cytokine production (Candia et al., 2021; Pérez-Pérez et al., 2017). Through these actions, leptin can alter both the composition and functional state of immune cells within the tumor microenvironment. In particular, obesity-associated hyperleptinemia has been implicated in promoting immune dysfunction by sustaining chronic inflammatory signaling, impairing cytotoxic immune responses, expanding immunosuppressive cell populations, and contributing to T cell exhaustion (Clements et al., 2018; Wang et al., 2019). These immunomodulatory effects may ultimately weaken antitumor immunity and facilitate tumor progression. Nevertheless, the role of leptin in cancer immunity is complex and context-dependent. Although many studies support the tumor-promoting and immunosuppressive actions of leptin, other evidence suggests that, under specific conditions, leptin can support certain immune cell functions and enhance anti-tumor responses. For instance, leptin has been reported to activate NK cell-mediated antitumor activity in a murine hepatocellular carcinoma model and to enhance CD8⁺ T cell metabolic fitness and effector function in selected contexts (Dudzinski et al., 2021; Elinav et al., 2006). These observations indicate that leptin should not be viewed simply as a uniformly tumor-promoting adipokine, but rather as a context-dependent immunometabolic regulator. In this review, we discuss current evidence regarding the roles of leptin signaling in tumor biology, immune dysregulation, and therapeutic strategies in obesity-associated cancers. A better understanding of leptin-driven mechanisms underlying immune remodeling may provide new insights into the development of precision therapeutic approaches for cancers associated with obesity. We propose that leptin functions as a context-dependent immunometabolic regulator that connects adiposity to tumor progression, immune remodeling, and responses to anticancer therapy. OVERVIEW OF LEPTIN SIGNALING AND ITS IMMUNE REGULATORY FUNCTIONS Leptin exerts its biological effects by binding to its cognate receptor, the leptin receptor (Lep-R or Ob-R), a member of the class 1 cytokine receptor superfamily. Several isoforms of Lep-R have been identified, including soluble, short, and long form isoforms. Among these, the long isoform, commonly referred to as Lep-Rb, contains the full intracellular signaling domain and is primarily responsible for canonical leptin signaling (Candia et al., 2021). Upon leptin binding, the long isoform of Lep-R undergoes conformational changes that promote Janus kinase 2 (JAK2) activation, followed by phosphorylation of specific tyrosine residues within the intracellular domain of the receptor. These phosphorylated residues serve as docking sites for downstream signaling molecules, including signal transducer and activator of transcription 3 (STAT3) and Src homology region 2 domain-containing phosphatase 2 (SHP2). Recruitment of SHP2 to Lep-Rb promotes its tyrosine phosphorylation and interaction with the adaptor protein growth factor receptor-bound protein 2 (GRB2), thereby activating the Ras/Raf/MEK/ERK signaling cascade. This pathway contributes to the induction of immediate-early response genes, including FOS, JUN, and JUNB. In parallel, binding of STAT3 to phosphorylated Lep-R leads to its phosphorylation, dimerization, and nuclear translocation, where it activates the transcription of target genes involved in cell survival, proliferation, inflammation, and metabolic regulation, including cyclin D1. Leptin-induced JAK2 activation can also stimulate the phosphoinositide 3-kinase (PI3K)/AKT pathway, thereby promoting cell growth, survival, metabolism, and resistance to apoptosis. Negative regulators, including protein tyrosine phosphatase 1B (PTP1B) and SOCS3, are induced as feedback mechanisms to restrain leptin signaling and prevent excessive pathway activation (Evans et al., 2021; Frühbeck, 2006). A schematic overview of the leptin signaling pathways is shown in Fig. 1. In obese individuals, circulating leptin levels are typically elevated in proportion to increased adiposity. However, despite high circulating leptin levels, impaired leptin responsiveness frequently develops, resulting in attenuated satiety signaling and progressive weight gain. This condition, commonly referred to as leptin resistance, is associated with defective leptin receptor signaling and impaired activation of downstream pathways, particularly JAK2/STAT3 signaling. Conversely, congenital leptin deficiency or severe defects in leptin receptor signaling results in profound obesity, underscoring the essential role of leptin signaling in energy homeostasis. Hyperleptinemia, a typical feature of obesity, is closely associated with various obesity-related metabolic abnormalities, including insulin resistance, altered lipid metabolism, mitochondrial stress, and chronic low-grade inflammation (Gregor and Hotamisligil, 2011; Rohm et al., 2022). These findings indicate that leptin signaling plays a critical role not only in energy balance but also in obesity-associated metabolic complications. Beyond its metabolic functions, leptin is increasingly recognized as an immunoregulatory adipokine whose effects are highly context-dependent. NK cells express both long and short isoforms of Lep-R and can directly respond to leptin stimulation. Leptin has been reported to promote NK cell maturation, proliferation, and cytolytic activity through activation of JAK2/STAT3-dependent signalling (Fernández-Riejos et al., 2010; Laue et al., 2015). However, the effect of leptin on NK cells appears to depend on the dose and duration of exposure. Short-term leptin stimulation can enhance NK cell cytotoxicity and IFN-γ production, whereas prolonged exposure to high leptin levels may induce functional leptin resistance and impair NK cell activity (Kiernan and MacIver, 2021). In obesity, NK cells exhibit diminished responsiveness to leptin, likely due to impaired downstream JAK/STAT3 signaling, resulting in reduced cytotoxic activity. These findings suggest that obesity-associated hyperleptinemia may paradoxically impair NK cell function despite the immune-supportive role of leptin under normal physiological conditions. Leptin also regulates T cell biology in a context-dependent manner. Physiological leptin signaling supports T cell survival, proliferation, and activation, particularly by promoting Th1-type immune responses and cytokine production. Leptin favors the production of pro-inflammatory cytokines such as IFN-γ and TNF-α and can facilitate Th17 differentiation, whereas leptin deficiency is associated with impaired T cell responses and increased susceptibility to infection (Pérez-Pérez et al., 2017). However, chronic hyperleptinemia in obesity may contribute to T cell dysfunction by sustaining inflammatory signaling, altering T cell metabolism, and impairing effective cytotoxic responses. Notably, within the tumor microenvironment, excessive leptin signaling may contribute to CD8⁺ T cell dysfunction by promoting metabolic stress, reducing cytotoxic effector function, and facilitating exhaustion-associated phenotypes (Wang et al., 2019). These observations support the concept that leptin functions as an immunometabolic regulator that can either support protective immunity or contribute to immune dysfunction depending on metabolic and inflammatory context. Macrophages are another important target of leptin-mediated immune regulation. Leptin promotes macrophage activation, chemotaxis, phagocytic activity, and pro-inflammatory cytokine production. In obesity, sustained leptin signaling may reinforce macrophage-driven inflammation by enhancing the production of pro-inflammatory cytokines, thereby contributing to systemic meta-inflammation. Leptin has also been reported to promote an M1-like macrophage phenotype and to regulate macrophage lipid metabolism through PI3K/mTOR-related pathways (Dudzinski et al., 2021). Within tumors, leptin may also influence macrophage polarization and function, potentially favoring a tumor-promoting inflammatory microenvironment. Collectively, current evidence demonstrates the dual and context-dependent role of leptin in immunity. Physiological leptin signaling is required for immune homeostasis and effective host defense. In contrast, chronic obesity-associated hyperleptinemia may induce leptin resistance, sustain low-grade inflammation, and promote immune dysregulation. During prolonged obesogenic states, leptin may shift from a homeostatic immune regulator to a pro-inflammatory and immunometabolic mediator that contributes to systemic inflammation and a tumor-permissive immune remodeling. Persistent leptin excess may also disrupt immune tolerance mechanisms. Leptin has been shown to negatively regulate regulatory T cell proliferation and function, whereas leptin deficiency or impaired leptin signaling is associated with increased Treg responses in several experimental settings (Rosa et al., 2007; Matarese et al., 2010). Consistently, elevated leptin levels have been linked to reduced CD4⁺CD25⁺ regulatory T cell abundance in autoimmune conditions such as multiple sclerosis, and leptin has been implicated in the pathogenesis of inflammatory and autoimmune diseases, including multiple sclerosis, psoriasis, systemic lupus erythematosus, and autoimmune thyroiditis (Matarese et al., 2005; Procaccini et al., 2015). In addition, recent studies on obesity-associated atherosclerosis suggest that leptin contributes to disease progression, whereas defective leptin production or impaired leptin receptor signaling can enhance regulatory T cell responses and reduce lesion formation (Raman and Khanal, 2021). Together, these findings identify leptin as a pivotal biological molecule linking obesity, metabolic inflammation, and immune dysregulation. Therefore, leptin signaling may represent a potential therapeutic target not only in obesity-associated inflammatory and autoimmune diseases, but also in cancers driven by obesity-induced dysfunction of cancer immunity. MODULATION OF TUMOR PROGRESSION BY LEPTIN There is a growing appreciation that increased adiposity is closely associated with the development, growth, and aggressiveness of various types of cancers. As a major adipocyte-derived hormone elevated under obese conditions, leptin has emerged as an important endocrine and paracrine mediator linking obesity to cancer progression. In addition to direct modulation of cancer cell proliferation and survival, leptin promotes angiogenesis and neovascularization within the tumor microenvironment (TME), thereby supporting tumor nourishment, expansion, and metastatic dissemination (Rose et al., 2002; Sierra-Honigmann et al., 1998). These findings indicate that leptin contributes to the establishment of tumor-permissive niche within the TME. Leptin-mediated tumor-promoting effects are mediated through multiple mechanisms, including activation of proliferative signaling pathways, suppression of apoptosis, induction of epithelial-mesenchymal transition (EMT), enhancement of stem-like phenotypes, promotion of angiogenesis, extracellular matrix remodeling, and modulation of stromal–tumor interactions. In the following section, we summarize current evidence regarding the effects of leptin on the development and progression of various types of cancers and discuss the underlying molecular mechanisms. Effect of leptin on breast cancer progression Elevated circulating leptin levels have been strongly associated with an increased risk of breast cancer, particularly in obesity-related and postmenopausal contexts (Wu et al., 2009). Clinically, leptin and leptin receptor expression levels are frequently higher in breast cancer tissues than in benign breast tissues (Wang et al., 2023), and their expression has been reported in both primary and metastatic breast cancer specimens (Garofalo et al., 2006; Kim, 2009). Mechanistically, leptin promotes breast cancer proliferation by activating multiple oncogenic pathways. In breast carcinoma cells, leptin enhances cyclin D1 promoter activity through STAT3-dependent transcriptional regulation and epigenetic modification involving histone acetylation and methylation (Saxena et al., 2007). In addition, leptin promotes proliferation through activation of the MAPK and PI3K/AKT pathways in both hormone receptor-positive and triple-negative cell lines (Laud et al., 2002; Okumura et al., 2002; Raut et al., 2019; Ray et al., 2007). Leptin also contributes to tumor progression by suppressing apoptosis. In obese mouse mammary tumor models, leptin signaling has been associated with reduced caspase-3 activation and decreased cleaved PARP expression (Dogan et al., 2007). Leptin enhances breast cancer progression by enhancing metastatic potential. In breast cancer models, including MCF-7 and MDA-MB 231 cells, leptin has been shown to induce EMT-associated phenotypes through upregulation of pyruvate kinase M2, activation of β-catenin signaling, and modulation of the AKT/GSK3β and MTA1/Wnt1 pathways (Wang et al., 2015; Wei et al., 2016; Yan et al., 2012). Moreover, adipocyte-derived IL-6 and leptin cooperatively enhance procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 (PLOD2) expression through JAK/STAT3 and PI3K/AKT pathways, thereby promoting extracellular matrix remodeling and breast cancer metastasis (He et al., 2018). Leptin also enhances migration and invasion by activating focal adhesion kinase (FAK) and Src signaling, accompanied by increased secretion of extracellular matrix-remodeling enzymes, including MMP-2 and MMP-9 (Juárez-Cruz et al., 2019). This effect is accompanied by increased secretion of extracellular matrix-remodeling enzymes. These findings indicate that leptin promotes a more invasive breast cancer phenotype through coordinated regulation of EMT, focal adhesion signaling, and matrix remodelling. Beyond the direct effects on cancer cells, leptin signaling also influences angiogenesis within the breast TME. In mouse mammary tumor models, inhibition of leptin signaling reduces mammary tumor growth and decreases vascular endothelial growth factor (VEGF) expression, highlighting the importance of leptin signaling in tumor angiogenesis (Rene Gonzalez et al., 2009). Consistently, leptin has been reported to upregulate VEGF in human and mouse mammary tumor cells, including 4T1, EMT6, and mouse mammary tumor cell models (Gonzalez-Perez et al., 2010). Notably, inhibition of IL-1 signaling blocks leptin-induced VEGF/VEGFR2 expression (Zhou et al., 2011), suggesting functional crosstalk between leptin and inflammatory pathways in regulating tumor angiogenesis. Leptin may also participate in stromal remodeling through interactions among tumor cells, fibroblasts, and adipocytes. In breast cancer, leptin can enhance local estrogen production and promote paracrine communication between epithelial tumor cells and adjacent adipose stromal cells (Andò et al., 2014; Gonzalez et al., 2009). Increased local estrogen signaling may upregulate inflammatory and growth-promote pathways in adipose stromal cells, whereas tumor-derived factors may impair adipocyte differentiation and promote fibroblast activation (Andò et al., 2014; Schäffler et al., 2007). Although this mechanism requires further clarification, it suggests that leptin may contribute not only to intrinsic cancer cell signaling but also to remodeling of the adipose-rich stromal compartment in breast cancer. Collectively, leptin promotes breast cancer progression through coordinated regulation of cancer cell proliferation, apoptosis resistance, EMT, migration, invasion, angiogenesis, and stromal remodeling. These multifaceted effects support the concept that leptin acts as a key obesity-associated mediator that links adipose tissue dysfunction to breast cancer aggressiveness. Effect of leptin on ovarian cancer progression Leptin has been implicated in ovarian cancer progression through multiple mechanisms. Previous studies have demonstrated that leptin promotes ovarian cancer cell proliferation, at least in part through crosstalk with estrogen receptor signaling. In estrogen receptor-transfected ovarian cancer cells, leptin significantly increased proliferation in ERα-expressing cells, whereas this effect was not evident in ERβ-expressing cells (Choi et al., 2011). Leptin-induced proliferation and estrogen receptor transactivation were attenuated by AG490, a pharmacological inhibitor of JAK2/STAT3 signaling, indicating that STAT3 activation plays a critical role in leptin-mediated ovarian cancer cell growth. Additional in vitro studies have demonstrated that leptin enhances cell cycle progression in ovarian cancer cells. In OVCAR-3 cells, leptin increased the expression of cyclins D and A, while suppressing the cell-cycle inhibitor p21 WAF1/CIP1. Leptin also inhibited DNA fragmentation and reduced pro-apoptotic signaling, indicating that leptin supports ovarian cancer cell survival as well as proliferation (Ptak et al., 2013). These findings suggest that leptin may facilitate ovarian cancer progression by coordinating cell cycle activation and apoptosis resistance. Beyond its effects on proliferation and survival, leptin may also regulate mesenchymal and stem-like phenotypes in ovarian cancer. Leptin has been shown to stimulate migration, invasion, and maintenance of cancer stem-like properties, particularly in ovarian cancer cells with high Lep-R expression, such as A2780 and UCI 101 cells (Kato et al., 2015). Recent evidence further suggests that leptin can promote EMT-associated features and stemness-related properties by modulating molecular mediators such as c-Jun and OTU deubiquitinase 1 (OTUD1), particularly in obesity-associated ovarian tumor contexts. In addition, leptin has been implicated in resistance to taxane-based chemotherapy, including paclitaxel and docetaxel, which primarily exert cytotoxic effects during the G2/M phase of the cell cycle (Kato et al., 2015; Gu et al., 2019; Wang et al., 2025b). Together, these findings indicate that leptin may promote ovarian cancer progression by integrating estrogen receptor-dependent signalling, STAT3 activation, EMT, and survival pathways. Notably, the relationship between leptin and ovarian cancer appears to differ from that observed in several other obesity-associated malignancies. Plasma leptin levels have been reported to be significantly reduced in patients with ovarian cancer, suggesting a possible inverse correlation between circulating leptin levels and ovarian cancer status (Mor et al., 2005). This observation raises the possibility that systemic leptin levels may not fully reflect local leptin-mediated signaling during cancer progression. Effect of leptin on brain tumor progression Leptin signaling has also been implicated in the progression of brain tumors, particularly high-grade gliomas. Although the brain is a central target organ for leptin-mediated regulation of appetite, energy balance, and neuroendocrine function, accumulating evidence suggests that leptin may also act locally within brain tumors to support malignant phenotypes. Expression levels of leptin and its receptor have been reported to be higher in brain tumor tissues than in normal brain tissues. Elevated expression of leptin and Lep-R appears to be more prominent in highly malignant brain tumors, including glioblastomas and anaplastic astrocytomas, whereas relatively lower expression levels have been observed in lower-grade tumors such as gangliogliomas and low-grade astrocytomas. Consistently, malignant C6 glioma cells exhibit higher expression of leptin and Lep-R than non-malignant astrocytes, suggesting that leptin signaling may be associated with the development and progression of higher-grade brain tumors (Han et al., 2014; Riolfi et al., 2010). Functionally, leptin enhances the migratory and invasive behavior of glioma cells. In C6 glioma cells, leptin increased cell migration and invasion by selectively inducing matrix metalloproteinase-13 (MMP-13) expression (Yeh et al., 2009). In this model, leptin stimulation enhanced glioma cell motility and upregulated MMP-13, whereas no marked changes were observed in MMP-2 or MMP-9 expression. Notably, neutralization or gene silencing of MMP-13 significantly attenuated leptin-induced migration and invasion, indicating that MMP-13 is a key mediator of leptin-driven glioma invasiveness. These findings suggest that leptin may contribute to brain tumor progression by promoting extracellular matrix remodeling and invasive tumor behavior. Leptin signaling has also been associated with glioma stem-like properties. Glioma stem-like cells contribute to tumor initiation, therapeutic resistance, recurrence, and invasive growth. Emerging evidence indicates that leptin/Lep-R signaling may enhance the invasive and stem-like characteristics of glioma cells, thereby contributing to aggressive tumor behavior and poor clinical outcomes (Han et al., 2014). Although further mechanistic studies are needed, these findings support the possibility that leptin signaling participates in the maintenance of malignant cellular phenotypes in brain tumors. In addition to local leptin signaling within brain tumors, systemic neuroendocrine regulation may indirectly influence tumor progression through modulation of leptin production. Previous studies using environmental enrichment models have shown that enriched environment conditions attenuate tumor growth and promote tumor regression in mice. Mechanistically, environmental enrichment increased hypothalamic expression of brain-derived neurotrophic factor (BDNF), and the tumor-suppressive effect of environmental enrichment was abolished by hypothalamic BDNF knockdown. Conversely, BDNF overexpression reduced tumor burden (Cao et al., 2010). Importantly, BDNF regulated adipose tissue function through β-adrenergic receptor-mediated sympathetic nervous system signaling, leading to reduced leptin production by adipose tissue and decreased circulating leptin levels. Although these findings were not limited to brain cancer models, they provide important evidence that the hypothalamic BDNF–sympathetic nervous system-leptin axis can systemically regulate tumor growth and may have therapeutic potential in cancer. Effect of leptin on gastric cancer progression The relationship between leptin and gastric cancer appears to be influenced by disease stage, local tumor expression, and the timing of sample collection. Clinically, reduced serum leptin concentrations have been reported in samples obtained from patients at the time of diagnosis, whereas increased leptin expression has been associated with poor prognosis in patients with poorly differentiated gastric tumors (Dülger et al., 2004; Zhao et al., 2007). These findings suggest that circulating leptin levels and local tumor-associated leptin signaling may not always change in parallel during gastric cancer progression. Experimental studies have provided mechanistic evidence supporting a tumor-promoting role of leptin in gastric cancer. Leptin stimulates gastric cancer cell proliferation through activation of STAT and ERK2 signaling pathways (Pai et al., 2005). Leptin also promotes gastric cancer cell motility by inducing intracellular adhesion molecule-1 (ICAM-1) expression. Relatively high expression levels of leptin and ICAM-1 have been observed in gastric cancer tissues and are correlated with lymph node metastasis. Mechanistically, leptin upregulates both membrane-bound and soluble ICAM-1 through activation of the Rho/Rho-associated kinase (ROCK) pathway and inhibition of Rho or ROCK significantly attenuates this response (Dong et al., 2014). Pai et al. (2005) directly linked leptin to STAT3/ERK2-dependent gastric cancer proliferation, while Dong et al. (2014), showed leptin-induced ICAM-1-dependent migration through Rho/ROCK signaling. Leptin has also been implicated in gastric tumor angiogenesis and stem-like phenotype. Immunohistochemical analyses from clinical specimens revealed a positive correlation between leptin and VEGF expression, supporting a potential pro-angiogenic role of leptin in GC (Zhao et al., 2007). More recent studies have further shown that leptin induces migration and invasion of gastric cancer cells by activating AKT and ERK signaling pathways and upregulating VEGF expression. In cancer-initiating cell populations isolated from gastric cancer, leptin maintained stemness and EMT marker expression, and promoted spheroid formation and invasion (Park et al., 2022). In addition to its direct tumor-promoting effects, leptin may also contribute to therapeutic resistance in gastro-oesophageal adenocarcinoma. Analysis of tumor biopsies from patients receiving platinum-based combination therapy identified enrichment of the adipokine signaling pathway, with elevated leptin mRNA levels correlating with a lack of radiological response. Consistently, increased tumor leptin expression was associated with poor treatment response in an independent patient cohort (Bain et al., 2014). These findings suggest that leptin may serve as an important mediator of chemoresistance in gastro-oesophageal malignancies. Effect of leptin on hepatic cancer progression Leptin appears to exert context-dependent effects on hepatocellular carcinoma (HCC), reflecting a complex relationship between adipokine signaling, immune regulation, and tumor biology. On the one hand, leptin has been reported to suppress HCC development in mice through activation of NK cells (Elinav et al., 2006). On the other hand, in obesity-associated HCC, adipose tissue-derived leptin contributes to tumor-promoting processes, particularly through TME remodeling. Several studies suggest that leptin signaling may participate in HCC development by influencing malignant cellular programs (Stefanou et al., 2010). Leptin has been shown to regulate human telomerase reverse transcriptase (hTERT), a key mediator of cellular immortalization and oncogenesis. In HCC cells, leptin-mediated hTERT overexpression may contribute to tumor growth and malignant progression (Stefanou et al., 2010). These findings suggest that leptin may support telomerase-associated oncogenic programs in hepatic cancer. Leptin also promotes HCC cell proliferation and protects HCC cells from apoptosis. Previous studies have indicated that TGF-β1 induces apoptotic signaling, characterized by degradation of poly (ADP-ribose) polymerase (PARP) and a reduced Bcl-2/Bax proportion. These effects are counteracted by leptin, which suppresses Bax expression and restores the Bcl-2/Bax balance, thereby increasing the survival of cancer cells. Mechanistically, leptin-driven activation of JAK2–PI3K/AKT and MEK/ERK1/2 signaling pathways mediates these proliferative and antiapoptotic effects (Chen et al., 2007). Moreover, leptin and Lep-R have been implicated in angiogenesis in HCC, supporting a broader role for leptin signaling in the advancement of hepatic cancer (Ribatti et al., 2008). Taken together, leptin contributes to HCC progression by supporting tumor-cell proliferation, inhibiting apoptosis, and enhancing telomerase-associated oncogenic signalling. Intriguingly, the previously reported anti-tumor activity mediated through NK cell activation suggests that the role of leptin in HCC is highly context-dependent and may vary according to metabolic status, immune composition, and disease stage. Effect of leptin on prostate cancer progression Leptin has been implicated in normal prostate development and vascularization, and accumulating evidence suggests a potential relationship between leptin signalling and prostate cancer risk, particularly in the context of obesity. Elevated circulating leptin concentrations have been associated with subsequent prostate cancer development in some clinical studies. Interestingly, intermediate leptin levels may correlate more strongly with prostate cancer risk than the highest leptin levels (Stattin et al., 2001), implying that a specific adiposity-related hormonal milieu may favor prostate carcinogenesis rather than a simple linear relationship between leptin concentration and cancer risk. In vitro studies further support a role for leptin in prostate cancer progression. Leptin stimulates proliferation primarily in androgen receptor (AR)-independent prostate cancer cell lines, such as DU145 and PC-3, whereas little or no proliferative effect has been observed in AR-dependent LNCaP-FGC cells, despite the presence of functional Lep-R isoforms. In this model, leptin activates JNK signaling in AR-independent cells, and pharmacological inhibition of JNK abrogates leptin-induced proliferation (Onuma et al., 2003). These findings suggest that JNK activation is a key mediator of leptin-driven growth in hormone-independent prostate cancer. In vitro studies also indicate that leptin enhances the migratory capacity of prostate cancer cells and increases VEGF expression, supporting a pro-angiogenic role for leptin in prostate cancer (Frankenberry et al., 2004). In addition, leptin promotes prostate cancer cell growth and survival by activating PI3K and ERK signaling pathways and suppressing apoptotic cell death, particularly in DU145 and PC-3 cells (Somasundar et al., 2004). Collectively, leptin may contribute to prostate cancer progression by preferentially supporting the proliferation of androgen-independent tumor cells, enhancing migration and angiogenic signaling, and suppressing apoptotic cell death. These observations are particularly relevant in the context of obesity, where elevated leptin levels may provide a hormonal and metabolic environment that favors prostate tumor progression. Effect of leptin on colorectal cancer progression Accumulating evidence suggests that leptin signaling is mechanistically linked to the development and progression of colorectal cancer (CRC), particularly in the context of obesity. Clinical studies have reported that elevated circulating leptin levels and increased Lep-R expression are associated with disease severity, suggesting their potential diagnostic or prognostic relevance in CRC (Drew, 2012; Jeong et al., 2015; Padidar et al., 2011). Consistent with these clinical observations, previous studies have shown that leptin promotes CRC cell proliferation, survival, and resistance to apoptosis, whereas inhibition of leptin signaling enhances TNF-α-induced apoptosis (Ogunwobi and Beales, 2007; Singh et al., 2020). Mechanistically, leptin activates multiple oncogenic signaling pathways in CRC cells, including AKT, ERK1/2, JAK2/STAT3, JNK, and activator protein-1 (AP-1). Leptin also promotes CRC progression through induction of metallopanstimulin-1 (MPS-1), which further activates the JNK/c-Jun signaling pathway. MPS-1 expression is positively associated with circulating leptin levels, advanced tumor stage, and poor survival in obese CRC patients. Conversely, inhibition of MPS-1 suppresses CRC cell growth and promotes apoptosis (Cao et al., 2019; Cascio et al., 2009; Hoda et al., 2007), supporting its role as a leptin-responsive mediator of CRC progression. Clinical evidence further suggests that leptin may influence metabolic and angiogenic features of CRC. Elevated circulating leptin levels have been associated with increased tumor glycolytic activity, enhanced angiogenesis, and therapeutic responses to VEGFR-targeted inhibition, indicating a potential link between leptin signaling, tumor metabolism, and vascular remodeling (Pommier et al., 2016). In addition, obesity-associated CRC has been linked to altered leptin signaling and genetic variations in the leptin gene, although further studies are required to define the clinical significance of leptin-related genetic and molecular alterations in CRC. Functionally, leptin has also been implicated in CRC cell adhesion, invasion, and metastatic potential, as supported by transcriptomic and proteomic analyses. Moreover, leptin signaling appears to contribute to chemotherapy resistance in obesity-associated CRC. In particular, leptin has been reported to reduce sensitivity to 5-fluorouracil (5-FU) by upregulating AXL receptor tyrosine kinase (AXL) expression and activating yes-associated protein (YAP) signaling (Chen et al., 2021). Collectively, these findings indicate that leptin promotes CRC progression through coordinated regulation of oncogenic, metabolic, angiogenic, invasive, and therapy-resistance pathways. Thus, the leptin/Lep-R axis may represent an important mechanistic link between obesity and CRC progression, although its clinical utility as a biomarker or therapeutic target requires further validation. IMMUNE REMODELING BY LEPTIN IN THE TUMOR MICROENVIRONMENT The immune system plays a crucial role in tumor surveillance and cancer progression through the coordinated actions of innate and adaptive immune responses. Within the TME, immune cells are continuously exposed to metabolic, inflammatory, and hormonal cues that shape their phenotype and function. Among adipocyte-derived factors, leptin has emerged as an important immunometabolic regulator that modulates immune cell activation, differentiation, cytotoxicity, and exhaustion. In particular, obesity-associated hyperleptinemia may contribute to immune remodeling within the TME by altering the metabolic fitness and effector functions of both innate and adaptive immune cells. In this section, we summarize the current evidence regarding leptin-mediated regulation of anti-tumor immunity, with a focus on its impact on innate and adaptive immune cell populations. Regulation of innate immunity by leptin Innate immune cells serve as the first line of defense against malignant transformation and play essential roles in tumor immune surveillance, inflammation, antigen presentation, and the initiation of adaptive immune responses. In cancer, innate immune populations can exert either anti-tumor or tumor-promoting functions depending on tumor type, disease stage, metabolic status, and the composition of the TME. Accumulating evidence indicates that leptin influences several components of innate immunity. These effects may be particularly relevant under obese conditions, where chronically elevated leptin levels coexist with systemic inflammation and metabolic stress. Leptin and natural killer cells: NK cells are cytotoxic lymphocytes of the innate immune system that provide early defense against virally infected and transformed cells and are essential mediators of tumor immune surveillance. Human NK cells express both long and short isoforms of the leptin receptor, allowing leptin to directly modulate NK cell activation and cytotoxic activity (Fernández-Riejos et al., 2010; Tian et al., 2002). The effects of leptin on NK cells appear to be dose, duration, and context dependent. In vitro studies have shown that leptin can modulate the expression of cytotoxic effector molecules. For example, treatment with a low concentration of leptin has been reported to increase granzyme B and TRAIL protein expression, while suppressing perforin expression, suggesting that leptin differentially regulates components of the NK cell cytotoxic machinery (Lamas et al., 2013). Short-term leptin stimulation can enhance NK cell activation, as reflected by increased IFN-γ production, CD69 expression, TRAIL induction, and tumor cell lysis. In contrast, prolonged exposure to leptin, which may occur in obesity-associated hyperleptinemia, appears to impair NK cell function. Long-term leptin exposure has been shown to reduce NK cell function and is associated with impaired JAK2-dependent signaling in peripheral blood mononuclear cells (Laue et al., 2015; Wrann et al., 2012), suggesting the development of leptin resistance. Consistently, NK cells from obese individuals show impaired cytotoxic potential, including altered expression of activation and degranulation markers such as CD69, TRAIL, granzyme B, and CD107a. These findings suggest that obesity-associated hyperleptinemia may paradoxically impair NK cell-mediated tumor surveillance despite the immune-supportive role of leptin under physiological conditions. Collectively, these findings indicate that leptin can exert both stimulatory and suppressive effects on NK cell-mediated anti-tumor immunity. While acute leptin signaling may enhance NK cell activation and cytotoxic responses, chronic hyperleptinemia in obesity may induce leptin resistance, functional exhaustion, and impaired tumor surveillance. Therefore, the role of leptin in NK cell biology should be interpreted in relation to exposure duration, leptin concentration, metabolic status, and the inflammatory context of the TME. Leptin and monocytes/macrophages: Monocytes are key components of the innate immune system and serve as precursors for macrophages and DC. Within the TME, macrophages exhibit remarkable plasticity and can acquire diverse functional phenotypes, ranging from classically activated, anti-tumorigenic M1-like macrophages to alternatively activated, pro-tumorigenic M2-like macrophages. Human monocytes express the long isoform of the leptin receptor, enabling them to directly respond to leptin stimulation. Consistently, leptin has been shown to regulate monocyte activation, cytokine production, and inflammatory responses (Zarkesh-Esfahani et al., 2001). Macrophages also express leptin receptor, although their expression levels may vary depending on macrophage activation status and tissue context. Leptin can function as a chemoattractant for monocytes and macrophages in vitro and activates multiple intracellular signaling pathways, including JAK/STAT, MAPK, and PI3K signalling. Through these pathways, leptin promotes macrophage migration, phagocytosis, intracellular calcium influx, and production of pro-inflammatory cytokines such as TNF-α, IL-6, IL-12, and IL-1β (Mancuso et al., 2002; Fernández-Riejos et al., 2010). These leptin-mediated effects may contribute to macrophage infiltration and inflammatory remodeling in metabolically stressed tissues, particularly under obese conditions (Gruen et al., 2007). In cancer, leptin-mediated regulation of macrophages appears to contribute to tumor-promoting inflammation and metastatic progression. In breast cancer models, leptin has been associated with increased tumor-associated macrophage accumulation and tumor growth and lung metastasis. Mechanistically, leptin-stimulated macrophages can activate NF-κB-dependent inflammatory pathways and promote tumor progression (Li et al., 2016). In addition, leptin induces IL-8 production in M2-like macrophages via leptin receptor-dependent activation of p38 MAPK and ERK signaling pathways, thereby facilitating breast cancer growth and metastasis (Cao et al., 2016). In colorectal cancer, leptin has been linked to macrophage metabolic reprogramming and tumor-supportive polarization. For example, leptin-induced production of itaconate, an immunomodulatory metabolite, has been suggested to suppress peroxisome proliferator-activated receptor-γ (PPAR-γ) activity, thereby favoring a tumor-supportive macrophage phenotype (Cao et al., 2016; Scheurlen et al., 2022). Collectively, these findings suggest that leptin contributes to tumor progression not only by acting directly on cancer cells but also by reshaping macrophage-mediated inflammatory and immunosuppressive circuits within the TME. Leptin and dendritic cells: DC are specialized antigen-presenting cells that play a central role in initiating anti-tumor immunity through antigen uptake, processing, and cross-presentation to T cells. However, within the immunosuppressive TME, DCs can acquire dysfunctional or tolerogenic phenotypes, resulting in impaired T cell priming and weakened anti-tumor immune responses. Leptin regulates DC biology in a context-dependent manner. Both immature and mature DCs express Lep-R, allowing leptin to modulate their survival, maturation, migration, and cytokine production. Leptin has been shown to promote differentiation and survival of human DCs by activating NF-κB-dependent upregulation of anti-apoptotic proteins, including Bcl-2 and Bcl-xL (Mattioli et al., 2005). Leptin also protects DCs from spontaneous and stress-induced apoptosis through NF-κB activation, Bcl-2/Bcl-xL induction, and PI3K/AKT signaling (Mattioli et al., 2009). In addition to its pro-survival effects, leptin promotes metabolic activation of DCs. Recent evidence indicates that leptin enhances glycolytic metabolism in DCs through the STAT3-hexokinase 2 (HK2) axis, thereby supporting DC activation and inflammatory function (Bai et al., 2021; Mattioli et al., 2005). Leptin also influences DC trafficking, as DC migration toward lymphoid organs is tightly linked to CCR7-dependent migratory programming and glycolytic metabolism, both of which are important for efficient T cell priming (Guak et al., 2018). Consistent with these findings, leptin deficiency has been associated with reduced expression of co-stimulatory molecules, including CD40, CD80, CD86, and MHC-II, as well as impaired DC maturation and trafficking (Moraes-Vieira et al., 2014). Overall, leptin appears to regulate DC activation, survival, migration, and metabolic fitness, thereby influencing T cell priming and the balance between anti-tumor immunity and tumor-promoting inflammation. However, the precise role of leptin-conditioned DCs within the TME remains incompletely defined and requires further investigation. Leptin and mast cells: Mast cells exhibit context-dependent roles in cancer, acting either as tumor-promoting inflammatory cells or as contributors to anti-tumor immunity depending on the composition and stage of the TME. These dual functions are largely mediated by the release of histamine, cytokines, chemokines, proteases, and angiogenic factors. Leptin has been reported to activate mast cells and amplify inflammatory mediator release. Mature tissue mast cells constitutively express leptin receptors, and leptin stimulation induces histamine secretion, cysteinyl leukotriene production, CCL2 generation, and chemokine release. These effects are associated with activation of intracellular signaling pathways, including PI3K and ERK1/2 (Żelechowska et al., 2019). In rat tissue mast cell models, leptin induced rapid degranulation histamine release, intracellular calcium influx, and migratory responses (Żelechowska et al., 2018). In addition, leptin-driven mast cell activation has been suggested to promote eosinophilic inflammation through mTOR-dependent signaling pathways in mouse models (Amorim et al., 2020), collectively indicating that leptin may amplify mast cell-mediated inflammatory responses. In the context of obesity-associated cancers, including breast, colorectal, and pancreatic cancers, the leptin–mast cell axis may contribute to a pro-inflammatory microenvironment that supports tumor progression (Amorim et al., 2020). However, given the context-dependent and sometimes paradoxical roles of mast cells in cancer, further studies are needed to clarify whether leptin-activated mast cells primarily promote or restrain tumor development in specific cancer types and disease stages. Leptin and neutrophils/basophils: Neutrophils are abundant innate immune cells that exert diverse and sometimes opposing functions in cancer. Depending on the TME conditions, neutrophils can acquire anti-tumorigenic N1-like or pro-tumorigenic N2-like phenotypes. Although neutrophils mainly express short isoforms of the leptin receptor, leptin can modulate neutrophil function directly or indirectly through inflammatory mediators such as TNF-α. Leptin has been shown to enhance neutrophil survival by inhibiting apoptosis through PI3K, MAPK, MEK/ERK, and NF-κB signaling pathways, thereby stabilizing mitochondrial integrity and suppressing caspase activation (Bruno et al., 2005; Sun et al., 2013). Leptin can also promote neutrophil recruitment and migration in vivo. Leptin-induced neutrophil migration depends on TNF-α/TNFR1 and CXCL1-mediated signaling pathways, suggesting that leptin may amplify neutrophilic inflammation through indirect inflammatory circuits (Souza-Almeida et al., 2018). These effects suggest that leptin may contribute to neutrophil-mediated inflammation within obesity-associated tumor microenvironments, although the specific role of leptin-regulated neutrophils in cancer remains insufficiently characterized. Basophils are relatively rare granulocytes but can influence immune responses through the release of cytokines, chemokines, and histamine (Souza-Almeida et al., 2018). Human basophils express leptin receptors, and their responsiveness to leptin may be enhanced by IL-33. Leptin has been reported to enhance basophil survival, migration, degranulation, and histamine release, and blockade of Lep-R attenuates basophil activation (Suzukawa et al., 2011). Although the role of leptin-regulated basophils in cancer remains less well defined than that of macrophages or neutrophils, these findings suggest that leptin may contribute to broader granulocyte-mediated inflammatory responses in the TME. Leptin and myeloid-derived suppressor cells: Myeloid-derived suppressor cells (MDSCs) are heterogeneous immature myeloid cells with potent immunosuppressive activity. In cancer, MDSCs promote tumor progression by suppressing cytotoxic T cell responses, impairing NK cell activity, and promoting regulatory T-cell expansion (Ostrand-Rosenberg, 2018). Obesity and high-fat diet conditions are associated with systemic inflammation and accumulation of MDSCs, providing a mechanistic link between metabolic dysfunction and tumor immune suppression. Leptin has been implicated in the expansion and accumulation of MDSCs under obese conditions. In high-fat diet-induced tumor models, leptin promotes tumor progression by inducing MDSC accumulation. Mechanistically, leptin acts through Lep-R-expressing myeloid cells and cooperates with obesity-associated inflammatory mediators, including IL-6, TNF-α, and prostaglandin E2 (PGE2), which are known to support MDSC recruitment, expansion, and suppressive function (Clements et al., 2018; Ostrand-Rosenberg, 2018). Interestingly, the relationship between leptin and MDSCs appears to be bidirectional. Leptin promotes the accumulation and immunosuppressive activity of MDSCs in obese tumor-bearing hosts, thereby facilitating tumor progression, whereas MDSCs can, in turn, downregulate leptin production and partially protect against obesity-associated metabolic dysfunction in certain contexts (Clements et al., 2018), suggesting that leptin–MDSC crosstalk may represent a regulatory circuit linking obesity-associated inflammation, systemic metabolism, and tumor immune suppression. Regulation of adaptive immunity by leptin Adaptive immunity plays a pivotal role in tumor immune surveillance and tumor control through antigen-specific immune responses. In particular, T and B lymphocytes coordinate cytotoxic activity, antibody production, cytokine secretion, and immune memory formation. Accumulating evidence indicates that leptin modulates adaptive immune responses by regulating lymphocyte metabolism, survival, differentiation, and effector functions. Because circulating leptin levels are markedly elevated in obesity, leptin-mediated regulation of adaptive immunity may represent an important mechanism linking metabolic dysregulation to altered anti-tumor immune responses. Leptin and T cells: T cells are central mediators of adaptive immunity and require substantial metabolic resources to sustain activation, proliferation, differentiation, and effector functions. Leptin functions as an immunometabolic signal that links systemic nutritional status to T cell immunity. In conditions of energy deprivation, such as fasting or leptin deficiency, T cell functions are impaired, whereas leptin supplementation can restore T cell activity and immune function (Lord et al., 1998; Saucillo et al., 2014), suggesting that physiological leptin signaling supports T-cell bioenergetics and immune competence. Leptin exerts context-dependent effects on cytotoxic CD8⁺ T cells. Under physiological conditions, leptin can support CD8⁺ T cell activation and effector function. However, in obesity-associated tumors, chronically elevated leptin may contribute to T cell dysfunction (Zhang et al., 2020). In obesity-associated breast cancer, leptin-enriched mammary adipose tissue suppresses CD8⁺ T cell function by activating STAT3-dependent fatty acid oxidation (FAO), while inhibiting glycolytic metabolism. This metabolic shift is associated with reduced tumor infiltration, impaired granzyme B production, and decreased effector cytokine production (Zhang et al., 2020). Consistently, obesity-associated elevation of leptin has been linked to increased PD-1 expression and T cell dysfunction in tumor-bearing mice and cancer patients (Wang et al., 2019). In this setting, genetic or therapeutic inhibition of STAT3 restores CD8⁺ T-cell glycolysis and effector function, supporting a critical role for the leptin–STAT3–FAO axis in obesity-associated T-cell dysfunction (Zhang et al., 2020). However, the impact of leptin on CD8⁺ T cell immunity may vary depending on tumor type, metabolic context, and tissue environment. For example, adipocyte-derived leptin induced by dietary fructose has been reported to counteract CD8⁺ T cell exhaustion and suppress lung tumor growth by attenuating terminal exhaustion-associated programming (Zhang et al., 2023). These findings suggest that leptin does not uniformly suppress anti-tumor T cell immunity. Rather, leptin may act as a context-dependent immunometabolic regulator whose effects are shaped by tumor type, metabolic state, and local adipocyte-immune cell interactions. Leptin also regulates CD4⁺ T cell differentiation, particularly the balance between regulatory T cells (Tregs) and T helper 17 (Th17) cells. Leptin has been shown to negatively regulate the proliferation of Foxp3⁺ Tregs, thereby limiting immune tolerance under certain inflammatory conditions (Rosa et al., 2007). In contrast, leptin receptor signaling promotes Th17 differentiation through STAT3-dependent pathways and the induction of the Th17-associated transcription factor RORγt, a master transcription factor required for Th17 lineage commitment (Reis et al., 2015). This reciprocal regulation of Treg and Th17 cells may amplify inflammatory responses. In cancer, however, the consequences of leptin-driven CD4⁺ T cell skewing are likely to be complex. Reduced Treg activity could potentially enhance anti-tumor immunity, whereas excessive Th17-associated inflammation may contribute to chronic inflammatory remodeling and tumor progression depending on the TME. Collectively, leptin acts as a key immunometabolic regulator of T cell immunity. By linking nutritional status, systemic inflammation, and T cell metabolism, leptin may either support protective T cell responses or promote T cell exhaustion and inflammatory dysregulation in obesity-associated cancers. Leptin and B cells: B cells are essential components of adaptive immunity and contribute to immune responses through antibody production and cytokine secretion. Accumulating evidence suggests that leptin can modulate B-cell survival, proliferation, inflammatory activation, and immune aging. Leptin supports B cell homeostasis by promoting cell survival and proliferation. Mechanistically, leptin signaling induces cell cycle progression and inhibits apoptosis through upregulation of genes, such as cyclin D1 and Bcl-2 (Chen et al., 2013). The promoting effects on B cell proliferation are mediated, at least in part, by transcriptional regulation and modulation of regulatory microRNAs targeting these survival- and cell-cycle-associated genes (Lam et al., 2010). These findings suggest that leptin can function as a trophic factor for B cells, helping maintain B cell viability and expansion under certain physiological conditions. In contrast, chronic leptin exposure, particularly in obesity and aging, may promote a pro-inflammatory and senescence-associated B cell phenotype. Leptin has been shown to upregulate inflammatory mediators, including IL-6, TNF-α, and IL-8, as well as immune-aging-associated molecules such as p16 and TLR4. In addition, leptin modulates microRNAs, including miR-16 and miR-155, which are associated with inflammatory activation and B cell dysfunction (Frasca et al., 2020). These changes resemble B cell alterations observed during obesity and aging, suggesting that leptin may contribute to intrinsic B cell inflammation and age-associated immune dysfunction. Thus, leptin appears to exert dual effects on B cells. On the one hand, it supports B cell survival and proliferation; on the other hand, persistent leptin signaling may drive inflammatory activation and immune dysregulation. In obesity-associated cancer, such leptin-mediated B cell remodeling may influence the TME by altering cytokine production, antibody responses, and interactions with other immune cells. However, compared with T cells and myeloid cells, the contribution of leptin-regulated B cells to tumor progression remains less clearly defined and warrants further investigation. Taken together, leptin regulates adaptive immunity by modulating the metabolic fitness, differentiation, survival, and effector functions of T and B lymphocytes. Under physiological conditions, leptin is required for optimal immune competence; however, chronic hyperleptinemia associated with obesity may contribute to CD8+ T cell exhaustion, inflammatory skewing of CD4⁺ T cell subsets, and pro-inflammatory remodeling of B cells. The context-dependent immunomodulatory effects of leptin signaling and their consequences for tumor progression are summarized in Table 1. Thus, leptin-mediated regulation of adaptive immunity represents a critical mechanism through which obesity-associated metabolic alterations shape anti-tumor immune responses and tumor progression. LEPTIN-DRIVEN METABOLIC REPROGRAMMING OF CANCER AND IMMUNE CELLS Metabolic reprogramming is a hallmark of cancer progression and therapeutic adaptation. In obesity, chronically elevated leptin levels may reshape metabolic pathways in both tumor and immune cells, thereby linking systemic metabolic dysregulation to tumor growth, immune dysfunction, and therapy resistance. In addition to its classical roles, leptin acts as an important metabolic signal within the TME, where it influences glucose metabolism, lipid utilization, mitochondrial activity, and stress-adaptive pathways. These leptin-driven metabolic alterations may provide cancer cells with bioenergetic and biosynthetic advantages while simultaneously contributing to immune dysfunction and tumor immune escape. Metabolic reprogramming of cancer cells driven by leptin signaling To sustain rapid proliferation, cancer cells undergo extensive metabolic rewiring, including enhanced glucose uptake, increased glycolytic flux, lipid metabolic remodeling, and mitochondrial adaptation. Leptin signaling has been implicated in these processes through activation of multiple oncogenic and metabolic signals, including PI3K/AKT, MAPK, JAK/STAT3, AMPK-related pathways, and HIF-1α-dependent programs (Pham et al., 2021; Saxena et al., 2007). One of the major metabolic effects of leptin in cancer cells is the regulation of glucose metabolism. In T cell lymphoma, leptin signaling has been associated with enhanced glucose uptake through increased expression and recruitment of glucose transporters (Han et al., 2018). Clinical and experimental studies on colorectal cancer have also suggested an association between circulating leptin levels, tumor glycolytic status, and patient outcomes (Pommier et al., 2016). In breast cancer cells, co-exposure to high glucose and leptin further enhances cell proliferation, at least in part, through accelerated cell cycle progression and modulation of metabolic signaling pathways (Okumura et al., 2002). These findings suggest that leptin may help coordinate host metabolic conditions, such as hyperglycemia and hyperleptinemia, with the bioenergetic demands of tumor cells. In addition to glucose metabolism, leptin plays an important role in lipid metabolic reprogramming. Cancer cells frequently increase de novo lipogenesis and fatty acid oxidation (FAO) to support membrane biosynthesis, redox balance, signaling processes, and energy production. In MCF7 breast cancer cells, leptin has been shown to enhance ATP production and promote metabolic adaptation by increasing FAO-associated pathways. Mechanistically, leptin induces AMPK phosphorylation and upregulates lipid metabolism-associated molecules, including FAT/CD36, CPT1, and PPARγ (Blanquer-Rosselló et al., 2016), suggesting that leptin may shift breast cancer cells toward increased lipid utilization and oxidative metabolism (Blanquer-Rosselló et al., 2015, 2016). Leptin-driven activation of the JAK/STAT3 pathway has also been linked to enhanced FAO, cancer stem cell maintenance, and chemoresistance. In breast cancer models, leptin enhances STAT3-dependent lipid metabolic programming and promotes the expression of FAO-related genes, such as CPT1B. Inhibition of this pathway reduces self-renewal capacity and increases chemotherapy sensitivity, suggesting that leptin-mediated lipid metabolism may contribute to tumor cell persistence and treatment resistance (Wang et al., 2018). Moreover, leptin may promote fatty acid metabolic remodeling through SREBP-1-associated lipid metabolism and autophagy-related pathways, thereby supporting tumor growth and survival (Pham et al., 2021). Although most of this evidence has been generated from cancer models, leptin-mediated activation of the LKB1–AMPK pathway has also been shown to enhance FAO in inflammatory disease settings, further supporting the broader role of leptin in fatty acid metabolic regulation (Wei et al., 2023). Beyond direct leptin signaling in tumor cells, obesity-associated adipose tissue may influence tumor metabolism through intercellular communication mediated by extracellular vesicles. Extracellular vesicles derived from obese adipose tissue have been reported to enhance Lep-R-mediated STAT3 signaling in breast cancer cells, thereby promoting FAO and malignant progression (Encarnação et al., 2025). Conversely, tumor-derived extracellular vesicles may also remodel host adipose tissue metabolism through leptin-related pathways. For instance, breast cancer-derived exosomal miR-204-5p has been reported to activate leptin signaling in white adipose tissue by promoting HIF-1α signaling. This process enhances lipolysis and browning of white adipose tissue and contributes to cancer-associated cachexia (Hu et al., 2023). These findings indicate that leptin-associated metabolic reprogramming is not restricted to cancer cells but may also participate in systemic metabolic crosstalk between tumors and adipose tissue. Mitochondrial adaptability is another important component of leptin-driven metabolic reprogramming. Under nutrient limitation, oxidative stress, and therapeutic pressure, cancer cells often rely on mitochondrial plasticity to maintain survival. In MCF-7 breast cancer cells, leptin enhances mitochondrial respiration and shifts ATP production from glycolysis toward oxidative phosphorylation, accompanied by reduced lactate production and increased expression of genes involved in mitochondrial biogenesis and dynamics (Blanquer-Rosselló et al., 2015). Leptin may also support tumor cell survival by regulating autophagy and mitochondrial metabolism. In hormone receptor-positive breast cancer cells, leptin induces autophagy, which contributes to cell proliferation, mitochondrial function, and ATP production (Raut et al., 2017). In triple-negative breast cancer cells, leptin enhances mitochondrial metabolism and glycolytic activity, thereby promoting migratory capacity (García-Miranda et al., 2024). These findings suggest that leptin supports metabolic plasticity across breast cancer subtypes, although the dominant metabolic pathway affected by leptin may vary according to tumor phenotype. In hematological malignancies, leptin signaling has been implicated in mitochondrial reprogramming and therapeutic resistance. In acute myeloid leukemia, leptin activates JAK2/STAT3-dependent mitochondrial remodeling, thereby enhancing oxidative phosphorylation and mitochondrial ROS production. This, in turn, induces antioxidant responses that promote leukemic cell survival and chemoresistance (Liao et al., 2026). In addition, leptin has been shown to increase FAO and proliferator-activated receptor coactivator-1α (PGC-1α) expression in breast cancer cells, thereby promoting mitochondrial biogenesis and resistance to apoptosis induced by NK cells (Bouguerra et al., 2020). These findings suggest that leptin-mediated mitochondrial remodeling may contribute not only to metabolic adaptation but also to immune evasion and therapeutic resistance. Importantly, leptin-induced metabolic effects appear to be tumor type- and context-dependent. While leptin promotes mitochondrial respiration, FAO, and oxidative metabolism in several breast cancer and hematological malignancy models, leptin has been reported to suppress mitochondrial respiration and oxidative capacity in HT116 colon cancer cells without significantly affecting cell viability (Yehuda-Shnaidman et al., 2013). This discrepancy suggests that the metabolic consequences of leptin signaling may depend on tumor lineage, nutrient availability, and the composition of the TME. Collectively, leptin promotes metabolic reprogramming in cancer cells by modulating glucose metabolism, lipid utilization, mitochondrial activity, and extracellular vesicle-mediated metabolic communication. These effects may provide tumor cells with adaptive advantages under obese conditions, supporting proliferation, survival, immune evasion, and chemoresistance. Therefore, leptin-driven metabolic reprogramming represents a key mechanism by which obesity-associated metabolic stress contributes to cancer progression. The modulatory effects of leptin signaling on metabolic reprogramming in cancer cells are summarized in Table 2. Immunometabolic regulation of immune cells by leptin signaling Emerging evidence indicates that leptin regulates immune cell metabolism in a context-dependent manner, thereby influencing the balance between anti-tumor immunity and tumor-promoting immune dysfunction. Because immune cell activation, differentiation, and cytotoxic activity are tightly linked to metabolic programs, leptin-induced metabolic remodeling may have profound consequences for immune responses within the TME. CD8⁺ T cells require metabolic flexibility to sustain proliferation, cytokine secretion, and cytotoxic effector functions. Upon activation, effector T cells generally increase glucose uptake and glycolysis to support rapid proliferation and effector molecule production, whereas memory-like T cells rely more heavily on mitochondrial oxidative metabolism and FAO to support long-term persistence. Under obesity-associated conditions, however, chronic leptin exposure may disrupt this metabolic balance. In obesity-associated breast cancer, leptin-enriched mammary adipose tissue promotes STAT3-dependent FAO, while suppressing glycolytic metabolism in CD8⁺ T cells. This metabolic shift is associated with impaired tumor infiltration and T cell exhaustion (Zhang et al., 2020). These findings suggest that excessive leptin signaling may contribute to CD8⁺ T cell dysfunction by redirecting cellular metabolism away from glycolysis-dependent effector activity. Immunometabolic remodeling by leptin has also been observed in other tumor contexts. In neuroblastoma, leptin signaling has been reported to dysregulate carnitine palmitoyltransferase 2 (CPT2), leading to impaired oxidative phosphorylation and increased lactate production. This metabolic alteration favors the differentiation of naïve CD4⁺ T cells toward regulatory T cells rather than Th17 cells, thereby creating an immunosuppressive environment that supports neuroblastoma proliferation, migration, and drug resistance (Li et al., 2025). These observations suggest that leptin may contribute to the establishment of an immunosuppressive metabolic niche that supports tumor progression. Leptin signaling has also been shown to regulate pathways involved in CD4⁺ T cell lineage commitment. Previous studies have shown that leptin signaling can promote Th17 differentiation through STAT3-dependent metabolic and transcriptional programs, including induction of RORγt (Reis et al., 2015). Through this mechanism, leptin may function as an immunometabolic checkpoint linking nutrient status, inflammatory cues, and T cell differentiation. However, the consequences of Th17 skewing in cancer are likely to be context-dependent, because Th17-associated inflammation can either support anti-tumor immunity or promote chronic inflammatory remodeling depending on tumor type, disease stage, and cytokine milieu. Importantly, leptin does not uniformly suppress anti-tumor immunity. Under certain therapeutic or experimental conditions, controlled leptin delivery may enhance T cell metabolic fitness and anti-tumor function. For example, oncolytic virus engineered to express leptin have been shown to reprogram tumor-infiltrating T cell metabolism by improving mitochondrial oxidative phosphorylation, thereby enhancing effector and memory-like functions (Rivadeneira et al., 2019). These findings indicate that the biological outcome of leptin signaling depends strongly on the context, including the level and duration of leptin exposure, tumor type, and mode of leptin delivery. Taken together, leptin functions as a context-dependent immunometabolic regulator within the TME. In obesity, sustained hyperleptinemia may contribute to T cell exhaustion, Treg-mediated immunosuppression, and tumor-permissive metabolic remodeling. In contrast, spatially and temporally controlled leptin signaling may enhance mitochondrial fitness and anti-tumor immune activity under specific therapeutic conditions. Thus, leptin-mediated immunometabolic regulation represents a critical mechanism linking obesity-associated metabolic stress to altered tumor immunity and cancer progression. The context-dependent immune remodeling induced by leptin within the TME is summarized in Fig. 2. LEPTIN AND THE IMMUNOTHERAPY PARADOX: DRIVER OF EXHAUSTION OR ENHANCER OF RESPONSE? As discussed above, leptin exerts context-dependent effects on tumor immunity by modulating both innate and adaptive immune compartments. Depending on the metabolic state of the host, the composition of the TME, and the duration and magnitude of leptin signaling, leptin may either enhance anti-tumor immune responses or contribute to immune dysfunction. This duality is particularly relevant to the so-called obesity immunotherapy paradox, in which obesity-associated metabolic dysregulation can promote tumor progression, yet overweight or obese patients may show improved responses to immune checkpoint blockade in certain cancer settings (Kichenadasse et al., 2020; Vick et al., 2023). Thus, leptin may act as either a driver of immune exhaustion or an enhancer of immunotherapeutic response depending on the biological context. Accumulating clinical and experimental evidence supports a potential role for leptin in shaping immunotherapy outcomes. In patients with extensive-stage small-cell lung cancer receiving maintenance immunotherapy, elevated circulating leptin levels have been associated with improved survival (Vita et al., 2023). Although this association does not necessarily establish causality, it suggests that leptin-related metabolic and immune states may influence therapeutic responses. Similarly, leptin can enhance the efficacy of anti-PD-1 checkpoint blockade by modulating tumor-associated macrophage polarization (Dudzinski et al., 2021). Mechanistically, leptin can promote the repolarization of tumor-associated macrophages (TAM) toward an M1-like phenotype, characterized by increased CD86 and MHC-II expression, thereby enhancing responsiveness to PD-1 blockade. Notably, this macrophage-dependent effect may occur even in obesity-associated TMEs with reduced lymphocyte frequency, suggesting that leptin may partly explain the obesity immunotherapy paradox by enhancing TAM-mediated responsiveness to checkpoint inhibition under specific conditions. Leptin may also enhance immunotherapy responses by improving T cell recruitment, activation, and metabolic fitness. In tumor-bearing mice, oncolytic viruses engineered to express leptin have been shown to remodel the metabolic state of tumor infiltrating T cells, increase T cell infiltration, enhance effector and memory-like function, and promote durable anti-tumor immunity (Harjes, 2019; Rivadeneira et al., 2019). These findings are consistent with the role of leptin as a nutritional and immunometabolic signal capable of supporting T cell activation when delivered in a spatially and temporally controlled manner. Similarly, leptin/LPS-treated DC have been reported to suppress breast cancer development and enhance anti-tumor immune responses (Basirjafar et al., 2024), suggesting that leptin may potentiate antigen-presenting cell function when combined with appropriate immune-activating signals. In contrast, chronic leptin signaling, particularly in obesity-associated tumors, may promote immune dysfunction and therapeutic resistance. Sustained leptin exposure can contribute to CD8⁺ T cell exhaustion by increasing inhibitory receptor expression, including PD-1, and by impairing proliferative and effector capacity (Wang et al., 2019). In obesity-associated breast cancer models, leptin-enriched adipose tissue promotes STAT3-dependent FAO in CD8⁺ T cells, while suppressing glycolytic metabolism, resulting in diminished granzyme B expression and impaired anti-tumor activity (Zhang et al., 2020). In addition, obesity-associated inflammatory and metabolic cues, leptin may alter macrophage checkpoint biology. Recent evidence indicates that obesity can induce PD-1 expression on tumor-associated macrophages, and that obesity-associated factors, including leptin, insulin, TNF-α, and palmitate, contribute to macrophage PD-1 induction in a metabolism-dependent manner (Bader et al., 2024). Therefore, although leptin can support immune activation under selected conditions, persistent leptin elevation may also reinforce immunosuppressive remodeling through T cell exhaustion, altered macrophage function, and metabolic dysregulation within the TME. These apparently opposing effects suggest that leptin should not be viewed simply as either beneficial or detrimental in cancer immunotherapy. Instead, leptin functions as a context-dependent immunometabolic regulator whose effects are determined by multiple variables, including systemic metabolic status, circulating leptin concentration, and treatment modality. From a therapeutic perspective, this raises the possibility that leptin signaling may need to be either enhanced or inhibited depending on the immunological and metabolic state of the patient. For example, transient or localized activation of leptin signaling may improve T cell or antigen-presenting cell function in selected therapeutic settings, whereas blockade of chronic leptin signaling may be beneficial in obesity-associated tumors. CONCLUSION AND FUTURE PERSPECTIVES Taken together, accumulating evidence indicates that leptin functions as a central immunometabolic mediator linking obesity-associated metabolic dysregulation to tumor progression and immune remodeling. By regulating tumor cell metabolism, myeloid cell polarization, and T cell exhaustion, leptin contributes to the establishment of a tumor-permissive microenvironment. These findings support the concept that leptin-mediated tumor–host crosstalk could be one of the key biological axes connecting obesity to cancer progression. However, the apparently conflicting findings discussed in this review suggest that leptin should not be regarded as a uniformly tumor-promoting or tumor-suppressive factor, but rather as a context-dependent immunometabolic regulator. For example, as discussed previously, leptin has been reported to suppress HCC growth by activating NK cell-mediated anti-tumor immunity, whereas, in obesity-associated HCC, leptin promotes tumor progression by inducing cancer cell survival signals and remodeling the TME. Likewise, leptin contributes to CD8⁺ T cell exhaustion in obesity-associated breast cancer, yet leptin has also been shown to attenuate terminal exhaustion and support anti-tumor T cell activity in a lung cancer model. Meanwhile, contrasting metabolic responses have also been reported in cancer cells: leptin enhances mitochondrial biogenesis and activity in breast cancer, whereas it suppresses oxidative capacity in colorectal cancer models. These seemingly divergent findings likely reflect differences in tumor lineage, metabolic phenotype, target cell type, disease stage, leptin concentration, duration of exposure, and local TME conditions. Thus, leptin may function as a context-sensitive immunometabolic rheostat whose biological effects are shaped by tissue-specific, temporal, and metabolic determinants. Targeting leptin-driven signaling may therefore provide a promising therapeutic strategy, particularly in obesity-associated cancers. In the context of immunotherapy, modulation of leptin signaling could potentially improve the efficacy of immune checkpoint blockade, cancer vaccines, and adoptive cell therapies, including CAR-T cell-based approaches. For example, therapeutic intervention in leptin-related pathways may restore the metabolic fitness of tumor-infiltrating immune cells, enhance cytotoxic T cell function, or reverse leptin-associated immune exhaustion. In addition, combination strategies targeting PD-1, CTLA-4, or CD274/PD-L1 together with leptin-associated signaling pathways may offer opportunities to overcome immunosuppressive remodeling in metabolically dysregulated TMEs. Several pharmacological approaches targeting the leptin axis have shown promise in preclinical studies. These include leptin receptor antagonists, such as the pegylated leptin peptide receptor antagonist 2 and leptin-binding site I-derived peptides, which have been shown to suppress leptin activity in cancer (Catalano et al., 2015; Gonzalez et al., 2009). In addition, anti-leptin neutralizing antibodies that directly block leptin-LepR signaling have been shown to attenuate leptin-mediated biological activity in preclinical models (Sun et al., 2025). Beyond direct targeting of leptin or LepR, inhibition of downstream leptin-associated pathways may provide clinically relevant alternatives. Among these, STAT3 inhibitors have shown particular promise in obesity-associated breast cancer models. For example, the small-molecule STAT3 inhibitor was shown to abrogate leptin and PD-L1-induced STAT3 activation in CD8⁺ T cells, thereby reversing fatty acid oxidation-dependent metabolic dysfunction, restoring glycolytic effector programming, and improving anti-tumor cytotoxic activity (Zhang et al., 2020). These findings suggest that STAT3 inhibition may indirectly counteract leptin-driven immunometabolic T cell exhaustion in selected tumor contexts. However, therapeutic targeting of downstream leptin signaling requires careful consideration. JAK2/STAT3 signaling also mediates physiological leptin functions in systemic metabolism and central energy homeostasis. For example, ruxolitinib, a JAK1/2 tyrosine kinase inhibitor, has been reported to interfere with physiological leptin signaling in the hypothalamus and has been associated with metabolic side effects, including weight gain, underscoring the limitations of non-selective downstream pathway inhibition (Mollé et al., 2020). These findings underscore the limitations of non-selective downstream pathway inhibition and highlight the need for tumor- or immune cell-targeted strategies that can selectively modulate pathological leptin signaling while preserving its physiological metabolic functions. Despite these therapeutic opportunities, the clinical translation of leptin-targeted approaches remains challenging. Leptin exerts highly context-dependent effects that vary according to systemic metabolic status. While chronic leptin elevation in obesity may promote tumor progression and immune dysfunction, leptin signaling may also support immune activation or enhance immunotherapeutic responses under selected conditions. Therefore, future studies should define the precise biological contexts in which leptin functions as a tumor-promoting factor versus an immune-supportive signal. In particular, molecular profiling, metabolic characterization, and immune monitoring should be incorporated into clinical studies to identify patient subgroups most likely to benefit from leptin-modulating interventions. Moreover, preclinical models that more accurately recapitulate obesity-associated metabolic inflammation and human tumor heterogeneity will be essential for evaluating leptin-targeted therapeutic strategies.